PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: Ocimum Biosolutions, Inc.

Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Ocimum Biosolutions Develops Sulfolobus Solfataricus Microarrays for SulfoSYS - Ocimum Biosolutions, a leading integrated global genomics company, proudly announces its association with the SulfoSYS project -
Ocimum Biosolutions Develops Sulfolobus Solfataricus Microarrays for SulfoSYS


NewswireToday - /newswire/ - Hyderabad, Andhra Pradesh, India, 2010/05/31 - Ocimum Biosolutions, a leading integrated global genomics company, proudly announces its association with the SulfoSYS project -

Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


In a project coordinated by Prof. John van der Oost, Ocimum Biosolutions constructed the genome microarray for Sulfolobus solfataricus – the archaeal model organism of choice for a systems biology approach to study the evolution and characteristics of central cellular functions in living cells.

Prof. John van der Oost said “We have very good experience with the mentioned microarrays, and we and other members of the Solfolobus Chip consortium were impressed by the quality of the slides provided.”

Ms. Anu Acharya, CEO of Ocimum Biosolutions said “For esteemed researchers like Prof. John van der Oost, who want to target specific genes, or small genomes, our OciChip™ custom microarrays have become the platform of choice. These cost-effective microarrays can be used on all open array platforms, unlike other proprietary technologies. In addition, our sophisticated bioinformatics expertise results in highly sensitive and specific microarrays. These twin benefits have helped us become the preferred partner of consortia like SulfoSYS.”

About SulfoSYS
In the SulfoSYS project, within the transnational SysMO initiative (,, 10 European partners study the central carbohydrate metabolism (CCM), i.e. the branched ED pathway of S. solfataricus and its regulation under temperature variation by the integration of genomic, transcriptomic, proteomic, metabolomic, kinetic and biochemical information as well as modeling. The long term goal of the project is to build a sufficiently precise replica for this part of the living cell “a Silicon Cell” to enable computation of life, particular its robustness to changes in temperature, at the system level.

About OciChip™ Custom Microarrays
OciChip™ Custom microarrays are epoxy-coated glass slides onto which the sequences from thousands of different genes are immobilized, or attached, at fixed locations. First, for each gene of interest, 50 to 70 mer oligonucleotides are bioinformatically designed excluding dimers and, secondary structure formation, thereby ensuring highly reproducible hybridization achieved by precisely defined GC-content/melting temperature. Then, based on the researcher’s study objective, the layout of these oligonucleotides on the microarray is bioinformatically designed with maximal reduction of cross-hybridization & avoiding background contamination. The oligonucleotides are then synthesized and QCed using mass-spectrometry. These oligonucleotides are then mechanically micro-spotted on the epoxy-coated glass slides.
Note: Apart from oligonucleotides, Ocimum also spots genomic DNA clones, cDNA, proteins, peptides, lipids, carbohydrates, and other small molecules.

About Ocimum Biosolutions

Ocimum Biosolutions ( is an integrated global genomic services company with operations in Hyderabad, India and Gaithersburg, MD. We provide comprehensive (research level and GLP-compliant) genomic services, reference databases, and LIMS solutions. Our distinct platform "Research as a Service" (RaaS) allows complete outsourcing of genomics – from storing biological samples and performing on demand DNA and RNA based services to validating biomarkers using our proprietary databases and providing data and bioinformatic analysis. We have been chosen as a global preferred outsourcing provider for more than 75% of top 25 pharma and biotech companies plus leading research institutes. Our partners recognize our expertise for understanding disease mechanisms in correlation with discovery, prioritization of gene targets and biomarkers, and sample analysis for clinical studies.

With our global infrastructure’s standardized procedures, capacity, and highly skilled staff, we are capable of supporting drug development programs from pre-clinical target development and toxicogenomic assessment to clinical biomarker identification and patient stratification. Our expertise is unparalleled and was gained through the creation of the world’s largest commercial gene expression databases – BioExpress® and ToxExpress®. Ocimum has been consistently ranked as India’s fastest growing biotechnology company and one of the fastest growing technology companies over the last five years by Deloitte Touche Tohmatsu.

Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


Written by / Agency / Source: Ocimum Biosolutions, Inc.


Availability: All Regions (Including Int'l)


Traffic Booster: [/] Quick Newswire Today Visibility Checker


Distribution / Indexing: [+] / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

# # #

  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!

Ocimum Biosolutions Develops Sulfolobus Solfataricus Microarrays for SulfoSYS

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

Publisher Contact: 
+91 40 66986700 row[.]
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Ocimum Biosolutions, Inc. securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Read Latest Articles From Ocimum Biosolutions, Inc. / Company Profile

Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

First European Patients Treated with DC Bead LUMI™ Radiopaque Drug-Eluting Beads
FDA Approves Genentech’s Lucentis (Ranibizumab Injection) for Diabetic Retinopathy
Biopharmaceutical Analytical Instrumentation Market Garners Strong Opportunities from Double-digit Growth in Biosimilars Finds Frost & Sullivan
BD Completes Acquisition of Caesarea Medical Electronics
MDxHealth and Ghent University Ink Licensing and Collaboration Agreements to Develop Cancer Biomarker Visualization Technology
Ipsen Completes Acquisition of ONIVYDE® (irinotecan liposome injection) and Additional Oncology Assets from Merrimack Pharmaceuticals
FDA Grants Breakthrough Therapy Designation for Rituxan® (Rituximab) in Pemphigus Vulgaris
MDxHealth Signs Agreement with Lab21 to Make SelectMDx Liquid Biopsy Test Available in the United Kingdom
Greenphire Drives Global Site Adoption of Clinical Trial Payment Solutions
Ipsen Announces MHRA Approval of New Indication for Decapeptyl® for the Treatment of Pre-menopausal Women with Early Stage Breast Cancer
SelectMDx Chosen by Michigan Medicine as Pre-biopsy Diagnostic Tool in Groundbreaking US Prostate Cancer Risk Clinic
BTG Announces CE Mark Certification for DC Bead LUMI™ - The First Commercially Available Radiopaque Drug-Eluting Bead
Sartorius to Acquire Real-time Live-cell Analysis Pioneer and Leader Essen BioScience
Pyxis™ ES System to Help U.S. Department of Defense Advance Medication Safety and Patient Care
BTG Receives U.S. FDA 510(k) Clearance for EKOS® Control Unit 4.0

Boost Your Social Network
& Crowdfunding Campaigns

NewswireToday Celebrates 10 Years in Business



Visit  La Bella Bakery Artisan Bakery Arizona

  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (